RS
ADCT icon

R Squared’s ADC Therapeutics ADCT Stock Holding History

R Squared’s Portfolio ADCT Stock Details ADCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$37.9K Buy
+10,119
New +$39.9K 0.02% 433
2025
Q4 		– Sell
-14,714
Closed -$58.9K – 516
2025
Q3 		$58.9K Buy
+14,714
New +$46.4K 0.03% 479

Other funds holding ADCT

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

R Squared's ADCT Position: Q1 2026 in Review

R Squared opened a new position in ADC Therapeutics (ADCT) in Q1 2026: 10,119 shares worth $37.9K. The stake represents 0.02% of the portfolio and ranks #433 among its holdings. This is a return to the name: R Squared previously reported a position in ADCT as recently as Q3 2025.

R Squared first reported a position in ADCT in Q3 2025 and has held it in 2 quarters since. The position peaked at $58.9K in Q3 2025. 118 funds tracked by Wall St. Rank hold ADCT as of Q1 2026.

  • R Squared held 10,119 shares of ADC Therapeutics worth $37.9K as of Q1 2026.
  • ADC Therapeutics was a new R Squared position in Q1 2026.
  • ADC Therapeutics made up 0.02% of R Squared's portfolio in Q1 2026, its #433 holding.
  • R Squared first reported a position in ADC Therapeutics in Q3 2025 and has held it in 2 quarters since.
  • R Squared's ADC Therapeutics position peaked at $58.9K in Q3 2025.
  • 118 funds tracked by Wall St. Rank held ADC Therapeutics as of Q1 2026.

Based on R Squared's 13F filing for Q1 2026, filed 29 Apr 2026.